# Vanda Pharmaceuticals Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Vanda Pharmaceuticals Inc.). ## Overview Vanda Pharmaceuticals Inc. is a U.S.-based biopharmaceutical company that develops and commercializes prescription medicines for neurological, sleep, psychiatric, and other specialty disease areas. Its portfolio includes marketed products such as Fanapt, HETLIOZ, PONVORY, and NERES, alongside a pipeline of additional indications and new drug candidates. ## Products & services • Fanapt® for bipolar I disorder and schizophrenia • HETLIOZ® for Non-24 and SMS sleep disturbances • PONVORY® for relapsing forms of multiple sclerosis • NEREUS™ for motion-induced vomiting prevention • Pipeline programs in psychiatry, immunology, and rare disease - **Commercial products** (85%) — Approved prescription medicines sold in the U.S. and select international markets. - **Sleep and circadian disorders** (35%) — HETLIOZ-based therapies for Non-24, SMS, and related sleep indications. - **Psychiatry** (25%) — Fanapt and related programs for schizophrenia, bipolar disorder, and depression. - **Neurology and immunology** (20%) — PONVORY and pipeline assets for multiple sclerosis and inflammatory diseases. - **Pipeline and partnered development** (15%) — Earlier-stage candidates across rare disease, GI, dermatology, and oncology. - Fanapt® for bipolar I disorder and schizophrenia - HETLIOZ® for Non-24 and SMS sleep disturbances - PONVORY® for relapsing forms of multiple sclerosis - NEREUS™ for motion-induced vomiting prevention - Pipeline programs in psychiatry, immunology, and rare disease ## Customers Vanda sells primarily to a limited number of U.S. pharmaceutical wholesalers, specialty pharmacies, and specialty distributors that then supply patients through the prescription channel. Demand is ultimately driven by physicians, patients, and third-party payors in specialty therapeutic areas, with reimbursement and formulary access playing a central role in uptake. Outside the U.S., the company also works through distribution partners in selected markets such as Israel and Germany. - **U.S. pharmaceutical wholesalers** (primary) — Buy Fanapt and other products for broad downstream distribution in the retail channel. - **Specialty pharmacies** (primary) — Dispense HETLIOZ and other specialty medicines to patients under restricted distribution. - **Specialty distributors** (primary) — Handle PONVORY fulfillment and inventory flow in the specialty prescription channel. - **International commercial partners** (secondary) — Distribute selected products such as Fanapt in Israel and HETLIOZ in Germany. - **Patients and prescribers** (primary) — End users and decision makers whose diagnosis, prescribing, and adherence drive demand. - U.S. wholesalers that stock and distribute Fanapt - Specialty pharmacies dispensing HETLIOZ to patients - Specialty distributors handling PONVORY fulfillment - International distribution partners in select markets - Physicians and payors influence end-demand and access ## Geography Vanda is headquartered in Washington, D.C. and commercializes its products primarily in the United States. It also has limited international activity through distribution of Fanapt in Israel and sales of HETLIOZ in Germany, which adds some geographic diversification but leaves the business largely U.S.-centric. - Headquartered in Washington, D.C. - Primary commercial market is the United States - Fanapt is distributed in Israel through a partner - HETLIOZ is sold in Germany - International revenue is limited versus U.S. sales ## Strategy Vanda’s strategy centers on maximizing the commercial performance of its marketed products while expanding them into additional indications and geographies. It also seeks to advance a pipeline built around genetics, genomics, and novel mechanisms, using both internal development and external licensing to broaden its future product base. - **Defend and grow the commercial portfolio** (short-term) — Current products fund the business and support the company’s commercial infrastructure. - **Expand label breadth for existing products** (medium-term) — Additional indications can extend product life cycles and broaden addressable markets. - **Build a differentiated pipeline** (medium-term) — New molecular assets reduce dependence on a small number of marketed products. - Maximize sales of Fanapt, HETLIOZ, PONVORY, and NEREUS - Expand approved products into new indications - Advance pipeline assets in psychiatry, GI, dermatology, and rare disease - Use genetics and genomics in discovery and clinical development - Pursue collaborations and licensing to add assets ## Risks Vanda depends on a small number of commercial products and a concentrated set of customers, so sales can be volatile and sensitive to inventory buying patterns, reimbursement, and generic competition. The company also faces patent litigation, regulatory risk, and clinical development uncertainty, all of which can affect product exclusivity, approvals, and future revenue streams. - **Generic competition for HETLIOZ and other products** [high] — Loss of exclusivity can materially reduce U.S. sales and market share. - **Customer concentration** [high] — A limited number of wholesalers and specialty pharmacies can drive quarter-to-quarter volatility. - **Patent and IP litigation** [high] — Enforcement and defense of patents consume resources and may not preserve exclusivity. - **Regulatory and clinical development risk** [medium] — Pipeline programs may fail in trials or be delayed by regulators. - **Reimbursement and pricing pressure** [medium] — Specialty drug demand depends on payor coverage and favorable reimbursement. - Revenue concentration in a few marketed products - Customer concentration among wholesalers and specialty pharmacies - Patent litigation and generic entry risk - Clinical trial and regulatory approval uncertainty - Reimbursement and market-access pressure in specialty drugs ## Accounting Revenue is recognized at a point in time when product control transfers to the customer, but reported net sales are reduced by rebates, chargebacks, co-pay assistance, returns, and prompt-pay discounts. Because these reserves rely on estimates and can resolve after period end, quarterly revenue can shift as assumptions about payer mix, inventory, and returns change; the company also uses allowances and valuation judgments for receivables, deferred tax assets, and contingent obligations. - **Revenue allowances and variable consideration** — Can materially affect quarterly revenue and gross-to-net trends - **Point-in-time revenue recognition** — Timing of wholesaler and specialty pharmacy orders affects period results - **Accounts receivable and credit loss estimates** — Bad-debt assumptions can move operating results - **Deferred tax asset valuation allowance** — Can create large non-cash swings in reported tax expense - **Contingent milestone and license obligations** — Affects liabilities and operating cash flow timing - Net product sales are recorded after rebates and discounts - Revenue is recognized when control transfers to the customer - Returns and rebates require estimates that can later change - Receivables depend on limited customer credit quality - Deferred tax asset valuation allowances can affect earnings --- *Last updated: 2026-04-29T05:07:25.798307+00:00*